Trial Profile
Phase 1-2 Trial of Systemically Administered VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Selected Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 Feb 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; VSV-IFNbeta-NIS (Primary)
- Indications Carcinoma; Neuroendocrine carcinoma; Non-small cell lung cancer; Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Vyriad
- 20 Jan 2024 Trial design, presented at the 2024 Gastrointestinal Cancers Symposium
- 13 Mar 2023 Planned number of patients changed from 40 to 70.
- 13 Mar 2023 Planned End Date changed from 1 Sep 2023 to 1 Dec 2023.